Theravance Biopharma, Inc. (TBPH) - Stock Analysis
Last updated: Jun 8, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠Quarterly Loss ⢠Large Deficit TBPH has very strong liquidity and cash generation with low leverage, but the latest quarter's loss and large accumulated deficit raise concerns about sustainability.
Price Behavior
Key Price Behavior Insights: ⢠Resistance Ceiling ⢠Support Rebound ⢠Breakout Needed Support Level: $15.58â$16.00 Resistance Level: $16.55â$16.70 TBPH is in a mild downtrend, with buyers defending roughly $15.58â$16.00 while rallies keep stalling at $16.55â$16.70, so the chart stays corrective unless it breaks resistance.
Sentiment & News
Key News Insights: ⢠Earnings beat ⢠Cost reduction ⢠Pipeline hurdle TBPH beat Q1 expectations and is leaning on restructuring and cost cuts to boost cash flow, but pipeline challenges still cloud the outlook.
AI Summary
TBPH should now be viewed as a cash-rich, restructuring-driven biotech rather than a pipeline-growth story, with upside hinging on management proving $60Mâ$70M of annualized cash flow by Q3 2026 through cost cuts, YUPELRI performance, and milestone income after the ampreloxetine setback.
Description
Theravance Biopharma is a biopharmaceutical company that researches, develops and commercializes respiratory medicines across the United States, Europe and Asia, with YUPELRI sold as a nebulized, once-daily therapy for COPD. Its clinical pipeline includes inhaled and gut-targeted small moleculesânotably several JAK inhibitors and other candidates addressing pulmonary and gastrointestinal disordersâalongside later-stage programs for autonomic and motility conditions. The company maintains licensing and collaboration agreements with major pharmaceutical partners and is incorporated in 2013 with headquarters in George Town, Cayman Islands.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 5 | Dec 12 | TBPH | Theravance Biopharma, Inc. | Theravance Biopharma benefits from record sales growth, upcoming Phase 3 CYPRESS data expected Q1 2026 as a key catalyst, positive technical momentum (+27% last month), and strong sector tailwinds, supporting near-term upside despite ongoing losses and high valuation. | Closed | -2.1% |